$81.89
Value $37.3B
GEHC and JNJ stock compared: price, dividend, valuation and results, from SEC filings.
$81.89
Value $37.3B
$267.14
Value $644B
GE HealthCare Technologies (GEHC) has a market value of $37.3B and Johnson & Johnson (JNJ) $644B. Over the last year, with dividends, GEHC moved +15.5% and JNJ +36.6%. The P/E is 17.3 for GEHC and 40.0 for JNJ. Dividend yield: GEHC 0.18%, JNJ 1.98%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
GEHC$37.3B
JNJ$644B
JNJ is 17 times GEHC
Revenue, 12 months
GEHC$21.6B
JNJ$99.3B
JNJ is 4.6 times GEHC
Net income, 12 months
GEHC$2.2B
JNJ$16.1B
JNJ is 7.5 times GEHC
Operating margin
GEHC13.3%
JNJ–
ROIC
GEHC11.1%
JNJ12.4%
1.3 points apart
P/E
GEHC17.3
JNJ40.0
JNJ is 2.3 times GEHC
Dividend yield
GEHC0.2%
JNJ2.0%
1.8 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
GEHC+12.8%
JNJ+94.2%
| Period | GEHCWith dividends | JNJWith dividends |
|---|---|---|
| 1 year since November 18, 2025 | +15.5%Price +15.3% | +36.6%Price +33.6% |
| 3 years since November 17, 2023 | +12.8%+4.1% a yearPrice +12.2% | +94.2%+24.8% a yearPrice +78.3% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
GEHCGE HealthCare TechnologiesJNJJohnson & Johnson
| Price | $81.89 | $267.14 |
|---|---|---|
| Market value | $37.3B | $644B |
| Enterprise value (EV) | $44.5B | $671B |
| P/E | 17.3 | 40.0 |
| P/E, 5-year median | 18.0 | 21.9 |
| P/B | 3.2 | 7.9 |
| EV/EBIT | 15.4 | 37.8 |
| Free cash flow yield | 5.1% | 3.2% |
| Revenue, 12 months | $21.6B | $99.3B |
|---|---|---|
| Net income, 12 months | $2.2B | $16.1B |
| Free cash flow, 12 months | $1.9B | $20.6B |
| Earnings per share, 12 months | $4.74 | $6.59 |
| Revenue growth, year on year | 4.8% | 6.1% |
| Revenue growth a year, past | +4.1%over 4 years | +2.7%over 5 years |
| EPS growth a year, past | -2.1%over 4 years | +14.9%over 5 years |
| Gross margin | 39.9% | 67.6% |
|---|---|---|
| Operating margin | 13.3% | – |
| Net margin | 10.0% | 16.2% |
| ROIC | 11.1% | 12.4% |
| ROE | 20.1% | 19.7% |
| Cash | $2.8B | $17.2B |
|---|---|---|
| Total debt | $10.4B | $44.7B |
| Net debt / EBITDA | 2.3 | 1.1 |
| Interest cover | 6.6× | 18.0× |
| Dividend yield | 0.2% | 2.0% |
|---|---|---|
| Dividend per share, 12 months | $0.15 | $5.28 |
| Dividend growth a year, past | – | +5.3%over 5 years |
| Buyback yield | 0.5% | 0.9% |
| Shareholder yield | 0.7% | 2.9% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Johnson & Johnson ($644B) is about 17.2 times GE HealthCare Technologies ($37.3B), at today's prices.
Since November 17, 2023, GEHC's price moved +12.2% and JNJ's +78.3%. With dividends: GEHC +12.8% (+4.1% a year), JNJ +94.2% (+24.8% a year). Past returns do not predict future ones.
The dividend yield at today's price is 0.18% for GE HealthCare Technologies and 1.98% for Johnson & Johnson. Over the last twelve months they paid $0.15 and $5.28 per share.
At today's price, the P/E is 17.3 for GEHC and 40.0 for JNJ. The median of the last five years was 18.0 and 21.9, which shows where each stands against its own past.
Over the last twelve months, the net margin was 10.0% for GE HealthCare Technologies and 16.2% for Johnson & Johnson, and the operating margin 13.3% and –. Revenue was $21.6B and $99.3B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.